ClinicalTrials.gov record
Completed Phase 4 Interventional Results available

Safety and Efficacy of PROMETRIUM® Capsules in Induction of Secretory Conversion

ClinicalTrials.gov ID: NCT00160199

Public ClinicalTrials.gov record NCT00160199. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 3:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Evaluation of Safety and Efficacy of PROMETRIUM® Capsules in Induction of Secretory Conversion of Endometrium and Withdrawal Bleeding in Subjects With Secondary Amenorrhea

Study identification

NCT ID
NCT00160199
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
Solvay Pharmaceuticals
Industry
Enrollment
240 participants

Conditions and interventions

Interventions

  • PROMETRIUM® 300 mg Drug
  • PROMETRIUM® 400 mg Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 45 Years
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2004
Primary completion
Jan 31, 2009
Completion
Jan 31, 2009
Last update posted
Jul 6, 2010

2004 – 2009

United States locations

U.S. sites
42
U.S. states
21
U.S. cities
39
Facility City State ZIP Site status
Site 29 Mobile Alabama
Site 41 Montgomery Alabama
Site 26 Tucson Arizona
Site 5 Jonesboro Arkansas
Site 39 Carmichael California
Site 17 Encinitas California
Site 10 San Diego California
Site 42 Avon Connecticut
Site 3 Groton Connecticut
Site 22 New Britian Connecticut
Site 9 Waterbury Connecticut
Site 37 West Hartford Connecticut
Site 14 Aventura Florida
Site 40 Clearwater Florida
Site 1 West Palm Beach Florida
Site 30 West Palm Beach Florida
Site 46 Atlanta Georgia
Site 43 Powder Springs Georgia
Site 36 Champaign Illinois
Site 12 Chicago Illinois
Site 6 Baton Rouge Louisiana
Site 7 Baltimore Maryland
Site 2 St Louis Missouri
Site 16 Reno Nevada
Site 45 New York New York
Site 23 New Bern North Carolina
Site 15 Winston-Salem North Carolina
Site 28 Winston-Salem North Carolina
Site 33 Cincinnati Ohio
Site 32 Erie Pennsylvania
Site 47 Hershey Pennsylvania
Site 44 Philadelphia Pennsylvania
Site 38 Pottstown Pennsylvania
Site 13 Greenville South Carolina
Site 8 Conroe Texas
Site 11 Corpus Christi Texas
Site 27 Houston Texas
Site 34 Houston Texas
Site 24 San Antonio Texas
Site 35 Salt Lake City Utah
Site 19 Norfolk Virginia
Site 4 Seattle Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00160199, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 6, 2010 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00160199 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →